katanin regulatory subunit B1 like 1 pseudogene 2Genealiases: []
Q-omics provides the consensus-scored KATNBL1P2 profile across patient tissues and cancer cell-line models. KATNBL1P2 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in CHOL. Among the 18 cancer types available for tumor–normal comparison, KATNBL1P2 is differentially expressed in 3, with the highest sampling consensus in THCA. Additionally, KATNBL1P2 RNA expression shows 7,703 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight CHOL, THCA, and LSCC as cancer lineages where KATNBL1P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KATNBL1P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KATNBL1P2 survival associations across molecular data types. KATNBL1P2 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KATNBL1P2 RNA expression–survival associations across cancer types. High KATNBL1P2 expression shows unfavorable associations in CHOL, ESCA, LGG and UCEC, but favorable associations in PAAD and OV. The CHOL Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CHOL as the clearest survival context for KATNBL1P2 RNA expression.
This table summarizes KATNBL1P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for KATNBL1P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KATNBL1P2 shows lower tumor expression in THCA and higher tumor expression in READ and STAD. The THCA box plot shows higher KATNBL1P2 RNA expression in normal versus tumor tissue (log2 FC = −0.090, t-test p = .012).
This table shows molecular features associated with KATNBL1P2 in patient tissues and cancer cell lines. In patient samples, KATNBL1P2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
